TABLE 2.

MIC distributions for agents against methicillin-resistant and methicillin-susceptible S. aureus

Antimicrobial agent	MRSAa (n = 2,093)				MSSAb (n = 2,038)
	MIC range (μg/ml)	MIC50 (μg/ml)	MIC90 (μg/ml)	S (%)c	MIC range (μg/ml)	MIC50 (μg/ml)	MIC90 (μg/ml)	S (%)c
Ceftaroline	0.06 to 2	0.5	1	98.9	≤0.03 to 1	0.25	0.25	100
Clindamycin	≤0.06 to >32	0.12	>32	76.6	≤0.06 to >32	0.12	0.12	95.4
Daptomycin	≤0.06 to 2	0.25	0.5	99.9	≤0.06 to 2	0.25	0.5	99.9
Erythromycin	0.12 to >32	>32	>32	9.7	≤0.06 to >32	0.5	>32	60.8
Levofloxacin	≤0.12 to >64	4	64	36.0	≤0.03 to >64	0.25	1	90.8
Linezolid	0.25 to 8	1	2	99.9	≤0.12 to 4	1	2	100
Oxacillin	0.25 to >16	>16	>16	0.2	≤0.06 to >16	0.5	1	99.2
Tigecycline	≤0.03 to 1	0.12	0.25	99.3d	≤0.03 to 1	0.12	0.25	99.9d
Tetracycline	≤0.06 to >64	0.25	0.5	95.9	≤0.06 to >64	0.25	0.5	95.5
TMP-SMX	≤0.03 to >64	0.06	0.12	97.0	≤0.03 to >64	0.06	0.12	97.6
Vancomycin	≤0.25 to 2	1	1	100	0.5 to 2	1	1	100

^aMethicillin-resistant S. aureus (MRSA) isolates were identified by a positive mecA PCR result.

^bMethicillin-susceptible S. aureus (MSSA) isolates were identified by a negative mecA PCR result.

^cSusceptibility (S) was determined using CLSI interpretive criteria, with the exceptions noted below.

^dThe FDA interpretive criterion for susceptibility is ≤0.5 μg/ml.